Focusing on the Identification and Management of Patients with Cancer-Associated Ischemic Stroke

doi:10.3969/j.issn.1673-5765.2025.02.001

Abstract

Abstract: Cancer-associated ischemic stroke (CAIS) is a disease with complex clinical manifestations, high risk of recurrence, and poor prognosis. Its pathogenesis is closely related to the activation of the coagulation system, but the specific mechanism has not been fully elucidated. At present, CAIS lacks effective screening and treatment strategies, leading to many challenges in its management. Therefore, multidisciplinary collaboration should be emphasized, early identification and standardized management of CAIS patients should be strengthened, and more relevant clinical research should be called for.

Key words: Cancer-associated ischemic stroke; Diagnosis; Treatment; Multidisciplinary collaboration

摘要： 肿瘤相关性缺血性卒中（cancer-associated ischemic stroke，CAIS）是一类临床表现复杂、复发风险高且预后不佳的疾病，其发病机制与凝血系统激活密切相关，但具体机制尚未完全阐明。目前，CAIS缺乏有效的筛查和治疗策略，导致其管理面临诸多挑战。因此，应重视多学科协作，加强对CAIS患者的早期识别与规范化管理，并呼吁开展更多相关临床研究。

关键词: 肿瘤相关性缺血性卒中; 诊断; 治疗; 多学科协作

CLC Number:

XU Bingdong, LIN Yingze, WANG Shuhong, YANG Danping, XU Anding, ZHANG Yusheng. Focusing on the Identification and Management of Patients with Cancer-Associated Ischemic Stroke[J]. Chinese Journal of Stroke, 2025, 20(2): 131-136.

徐炳东, 林英泽, 王舒泓, 杨丹萍, 徐安定, 张玉生. 重视肿瘤相关性缺血性卒中患者的识别与管理[J]. 中国卒中杂志, 2025, 20(2): 131-136.

Add to citation manager EndNote|Ris|BibTeX

URL: https://www.chinastroke.org.cn/EN/10.3969/j.issn.1673-5765.2025.02.001

https://www.chinastroke.org.cn/EN/Y2025/V20/I2/131

References

[1] NAVI B B，REINER A S，KAMEL H，et al. Risk of arterial thromboembolism in patients with cancer[J]. J Am Coll Cardiol，2017，70（8）：926-938.
[2] MULDER F I，HORVÁTH-PUHÓ E，VAN ES N，et al. Arterial thromboembolism in cancer patients：a Danish population-based cohort study[J]. JACC CardioOncol，2021，3（2）：205-218.
[3] COSTAMAGNA G，NAVI B B，BEYELER M，et al. Ischemic stroke in cancer：mechanisms，biomarkers，and implications for treatment[J]. Semin Thromb Hemost，2024，50（3）：342-359.
[4] GUO L J，WANG L L，LIU W H. Ability of the number of territories involved on DWI-MRI to predict occult systemic malignancy in cryptogenic stroke patients[J/OL]. J Stroke Cerebrovasc Dis，2020，29（7）：104823[2024-12-11]. https://doi.org/10.1016/j.jstrokecerebrovasdis.2020.104823.
[5] NOUH A M，STAFF I，FINELLI P F. Three territory sign：an MRI marker of malignancy-related ischemic stroke（Trousseau syndrome）[J]. Neurol Clin Pract，2019，9（2）：124-128.
[6] PARK M G，OH S J，BAIK S K，et al. Susceptibility-weighted imaging for detection of thrombus in acute cardioembolic stroke[J]. J Stroke，2016，18（1）：73-79.
[7] IKEDA H，ISHIBASHI R，KINOSADA M，et al. Factors related to white thrombi in acute ischemic stroke in cancer patients[J]. Neuroradiol J，2023，36（4）：453-459.
[8] BEYELER M，BELACHEW N F，KIELKOPF M，et al. Absence of susceptibility vessel sign in patients with malignancy-related acute ischemic stroke treated with mechanical thrombectomy[J/OL]. Front Neurol，2022，13：930635[2024-12-11]. https://doi.org/10.3389/fneur.2022.930635.
[9] CHEN J，ZHANG Z，NIE X M，et al. Predictive value of thrombus susceptibility for cardioembolic stroke by quantitative susceptibility mapping[J]. Quant Imaging Med Surg，2022，12（1）：550-557.
[10] TOI S，HIGUCHI E，HOSOYA M，et al. Association of transcranial Doppler microembolic signal with short-term mortality in acute ischemic stroke and active cancer[J/OL]. J Am Heart Assoc，2024，13（15）：e033634[2024-12-11]. https://doi.org/10.1161/JAHA.123.033634.
[11] SEOK J M，KIM S G，KIM J W，et al. Coagulopathy and embolic signal in cancer patients with ischemic stroke[J]. Ann Neurol，2010，68（2）：213-219.
[12] ZMAILI M A，ALZUBI J M，KOCYIGIT D，et al. A contemporary 20-year cleveland clinic experience of nonbacterial thrombotic endocarditis：etiology，echocardiographic imaging，management，and outcomes[J]. Am J Med，2021，134（3）：361-369.
[13] NAVI B B，ZHANG C，SHERMAN C P，et al. Ischemic stroke with cancer：hematologic and embolic biomarkers and clinical outcomes[J]. J Thromb Haemost，2022，20（9）：2046-2057.
[14] 李卓然，徐志秀，张梦. 恶性肿瘤合并Trousseau综合征急性脑梗死表现患者临床特征及预后因素分析[J]. 肿瘤基础与临床，2023，36（5）：405-408.
LI Z R，XU Z X，ZHANG M. Clinical characteristics and prognostic factors of malignant tumor patients with Trousseau syndrome manifesting as acute cerebral infarction[J]. Journal of Basic and Clinical Oncology，2023，36（5）：405-408.
[15] KASSUBEK R，BULLINGER L，KASSUBEK J，et al. Identifying ischemic stroke associated with cancer：a multiple model derived from a case-control analysis[J]. J Neurol，2017，264（4）：781-791.
[16] KASSUBEK R，WINTER M G R，DREYHAUPT J，et al. Development of an algorithm for identifying paraneoplastic ischemic stroke in association with lung，pancreatic，and colorectal cancer[J/OL]. Ther Adv Neurol Disord，2024，17：17562864241239123[2024-12-11]. https://doi.org/10.1177/17562864241239123.
[17] BRENNER A W，SU G H，MOMEN-HERAVI F. Isolation of extracellular vesicles for cancer diagnosis and functional studies[J/OL]. Methods Mol Biol，2019，1882：229-237[2024-12-11]. https://doi.org/10.1007/978-1-4939-8879-2_21.
[18] 吴俊汎，李冬云，姚梦丹，等. 中性粒细胞胞外诱捕网在肿瘤进展与高凝状态中的作用及应用进展[J]. 医学综述，2023，29（15）：2980-2986.
WU J F，LI D Y，YAO M D，et al. The role and application progress of neutrophil extracellular traps in tumor progression and hypercoagulability[J]. Medical Recapitulate，2023，29（15）：2980-2986.
[19] MURTHY S B，KARANTH S，SHAH S，et al. Thrombolysis for acute ischemic stroke in patients with cancer：a population study[J]. Stroke，2013，44（12）：3573-3576.
[20] HUANG S，LU X，TANG L V，et al. Efficacy and safety of intravenous thrombolysis for acute ischemic stroke in cancer patients：a systemic review and meta-analysis[J]. Am J Transl Res，2020，12（8）：4795-4806.
[21] POWERS W J，RABINSTEIN A A，ACKERSON T，et al. Guidelines for the early management of patients with acute ischemic stroke：2019 update to the 2018 guidelines for the early management of acute ischemic stroke：a guideline for healthcare professionals from the American Heart Association/American Stroke Association[J/OL]. Stroke，2019，50（12）：e344-e418[2024-12-11]. https://doi.org/10.1161/STR.0000000000000211.
[22] 刘丽萍，周宏宇，段婉莹，等. 中国脑血管病临床管理指南（第2版）（节选）——第4章缺血性脑血管病临床管理推荐意见[J]. 中国卒中杂志，2023，18（8）：910-933.
LIU L P，ZHOU H Y，DUAN W Y，et al. Chinese Stroke Association guidelines for clinical management of cerebrovascular diseases（second edition）（excerpt）—chapter four clinical management of ischaemic cerebrovascular diseases[J]. Chin J Stroke，2023，18（8）：910-933.
[23] ALOIZOU A M，PALAIODIMOU L，ALOIZOU D，et al. Acute reperfusion treatment and secondary prevention of cancer-related stroke：comprehensive overview and proposal of clinical algorithm[J/OL]. Ther Adv Neurol Disord，2023，16：17562864231180717[2024-12-11]. https://doi.org/10.1177/17562864231180717.
[24] CHO B H，YOON W，KIM J T，et al. Outcomes of endovascular treatment in acute ischemic stroke patients with current malignancy[J]. Neurol Sci，2020，41（2）：379-385.
[25] WŁODARCZYK E，WRONA P，HOMA T，et al. Long-term outcomes of mechanical thrombectomy in acute ischaemic stroke patients with concomitant malignancy[J]. Postepy Kardiol Interwencyjnej，2024，20（1）：95-102.
[26] JOLUGBO P，ARIËNS R A S. Thrombus composition and efficacy of thrombolysis and thrombectomy in acute ischemic stroke[J]. Stroke，2021，52（3）：1131-1142.
[27] VERSCHOOF M A，GROOT A E，DE BRUIJN S F T M，et al. Clinical outcome after endovascular treatment in patients with active cancer and ischemic stroke：a MR CLEAN registry substudy[J/OL]. Neurology，2022，98（10）：e993-e1001[2024-12-11]. https://doi.org/10.1212/WNL.0000000000013316.
[28] LETTERI F，PRACUCCI G，SAIA V，et al. Endovascular treatment in patients with acute ischemic stroke and comorbid cancer：analysis of the Italian registry of endovascular treatment in acute stroke[J/OL]. Stroke Vasc Interv Neurol，2023，3（3）：e000423[2024-12-11]. https://doi.org/10.1161/SVIN.122.000423.
[29] LEE M J，CHUNG J W，AHN M J，et al. Hypercoagulability and mortality of patients with stroke and active cancer：the OASIS-CANCER study[J]. J Stroke，2017，19（1）：77-87.
[30] JANG H，LEE J J，LEE M J，et al. Comparison of enoxaparin and warfarin for secondary prevention of cancer-associated stroke[J/OL]. J Oncol，2015，2015：502089[2024-12-11]. https://doi.org/10.1155/2015/502089.
[31] NAVI B B，MARSHALL R S，BOBROW D，et al. Enoxaparin vs. aspirin in patients with cancer and ischemic stroke：the TEACH pilot randomized clinical trial[J]. JAMA Neurol，2018，75（3）：379-381.
[32] NAVI B B，ZHANG C，MILLER B，et al. Apixaban vs. aspirin in patients with cancer and cryptogenic stroke：a post hoc analysis of the ARCADIA randomized clinical trial[J]. JAMA Neurol，2024，81（9）：958-965.
[33] CHUNG J W，HWANG J，KIM H J，et al. Edoxaban for the treatment of hypercoagulability and cerebral thromboembolism associated with cancer：a randomized clinical trial of biomarker targets[J]. Int J Stroke，2024，19（6）：645-653.
[34] EIKELBOOM J W，CONNOLLY S J，BOSCH J，et al. Rivaroxaban with or without aspirin in stable cardiovascular disease[J]. N Engl J Med，2017，377（14）：1319-1330.
[35] COSTAMAGNA G，HOTTINGER A，MILIONIS H，et al. Clinical and demographic characteristics，mechanisms，and outcomes in patients with acute ischemic stroke and newly diagnosed or known active cancer[J/OL]. Neurology，2023，100（24）：e2477-e2489[2024-12-11]. https://doi.org/10.1212/WNL.0000000000207341.
[36] DE STEFANO V，CAROBBIO A，DI LAZZARO V，et al. Benefit-risk profile of cytoreductive drugs along with antiplatelet and antithrombotic therapy after transient ischemic attack or ischemic stroke in myeloproliferative neoplasms[J/OL]. Blood Cancer J，2018，8（3）：25[2024-12-11]. https://doi.org/10.1038/s41408-018-0048-9.